Eli Lilly vs Merck: Revenue, Profit and Business Model
Eli Lilly had $65.2B of annual revenue in FY2025 and $20.6B of net income. Merck had $65B of annual revenue in FY2025 and $18.3B of net income.
Latest financial snapshot
Financial summary
Eli Lilly
Revenue rose from $28.5 billion in 2022 to $45.0 billion in 2024 and $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. Growth accelerated again in 2026: second-quarter revenue rose 48% to $23.0 billion, with Mounjaro at $9.94 billion (up 91%) and Zepbound at $4.93 billion. Lilly raised 2026 revenue guidance to $85-87 billion and non-GAAP EPS guidance to $35.50-36.50. Capital expenditures reached $7.8 billion in 2025 as Lilly expanded production capacity. Eli Lilly and Company is a pharmaceutical titan that has experienced massive growth, commanding a monumental market valuation frequently exceeding $700 billion.
Merck
Merck reported $65.0 billion in 2025 sales, up 1% from $64.2 billion in 2024, and $18.3 billion in net income attributable to Merck. Keytruda/Keytruda Qlex grew 7% to $31.7 billion, offsetting a 39% Gardasil decline. Momentum continued in 2026: Q2 2026 sales rose 5% to $16.6 billion, with Keytruda at $8.4 billion (including $463 million from Keytruda Qlex), Winrevair up 75% to $588 million and Animal Health up 8% to $1.8 billion. A $2.31-per-share charge for the Terns acquisition produced a Q2 GAAP net loss of $1.3 billion. In August 2026 Merck raised its full-year 2026 sales outlook to $66.3 billion to $67.3 billion, with non-GAAP EPS of $2.66 to $2.76 after Terns-related charges. Merck & Co. commands a robust market valuation frequently over $300 billion, driven heavily by its blockbuster oncology drug Keytruda.
Revenue and profit by year
Eli Lilly
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $65.2B | $20.6B | 31.7% | +44.7% | Source |
| FY2024 | $45B | $10.6B | 23.5% | +32.0% | Source |
| FY2023 | $34.1B | $5.2B | 15.4% | +19.6% | Source |
| FY2022 | $28.5B | $6.2B | 21.9% | +0.8% | Source |
| FY2021 | $28.3B | $5.6B | 19.7% | +15.4% | Source |
| FY2020 | $24.5B | $6.2B | 25.2% | +9.9% | Source |
| FY2019 | $22.3B | $8.3B | 37.3% | +3.8% | Source |
| FY2018 | $21.5B | $3.2B | 15.0% | +7.6% | Source |
| FY2017 | $20B | -$204.1M | -1.0% | -5.9% | Source |
| FY2016 | $21.2B | — | — | — | Source |
Merck
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $65B | $18.3B | 28.1% | +1.3% | Source |
| FY2024 | $64.2B | $17.1B | 26.7% | +6.7% | Source |
| FY2023 | $60.1B | $365M | 0.6% | +1.4% | Source |
| FY2022 | $59.3B | $14.5B | 24.5% | +21.7% | Source |
| FY2021 | $48.7B | $13B | 26.8% | +17.3% | Source |
| FY2020 | $41.5B | $7.1B | 17.0% | +6.1% | Source |
| FY2019 | $39.1B | $9.8B | 25.2% | -7.5% | Source |
| FY2018 | $42.3B | $6.2B | 14.7% | +5.4% | Source |
| FY2017 | $40.1B | $2.4B | 6.0% | +0.8% | Source |
| FY2016 | $39.8B | $3.9B | 9.8% | — | Source |
Where the revenue comes from
Eli Lilly
- Branded Prescription MedicinesPrimary
Sales of patent-protected medicines through wholesalers, pharmacies, health systems, and international channels.
- Collaborations and Licensing
Supporting
Milestones, royalties, and collaboration economics connected to research, development, and commercialization partnerships.
Merck
- Keytruda (pembrolizumab)
~US$31.7B in FY2025; approximately 49% of total company sales; highest-margin segment product
Keytruda is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor on T-cells, which restores
- Gardasil / Gardasil 9
~US$5.2B in FY2025 (down 39% from US$8.6B in FY2024); second-largest product; global market leader in HPV cancer prevention
Gardasil and its successor nine-valent formulation Gardasil 9 are prophylactic vaccines that prevent infection by the hu
- Winrevair (sotatercept)
~US$1.4B in FY2025 (US$419M in partial FY2024); fastest-growing new product; projected US$3-5B annual peak sales
Winrevair is a first-in-class activin signaling inhibitor approved by the FDA in March 2024 for the treatment of pulmona
- Januvia / Janumet (sitagliptin)
~US$2.5B in FY2025 (up 12% from US$2.3B in FY2024); mature franchise under competitive pressure from GLP-1 agents and generics
Januvia (sitagliptin) and the fixed-dose combination Janumet (sitagliptin plus metformin) are dipeptidyl peptidase-4 inh
Business model and strategy
Eli Lilly
How it makes money
Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience.
Growth strategy
Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (orforglipron) was approved by the FDA on April 1, 2026 and launched through LillyDirect, telehealth and U.S. retail pharmacies. Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in Phase 3.
Competitive advantage
Eli Lilly's formidable economic moat is founded on its multi-decade dominance in peptide synthesis, patent-protected intellectual property, and extensive global sterile manufacturing infrastructure.
Merck
How it makes money
Merck & Co., Inc. (known as MSD outside the United States and Canada) is an innovation-led global biopharmaceutical company that discovers, develops, and delivers prescription medicines, vaccines, biologic therapies, and animal health products. The company's business model is divided into two reporting segments: Pharmaceutical and Animal Health.
Growth strategy
Merck's strategy is to use Keytruda cash flow to build a broader portfolio before 2028. It moved patients toward subcutaneous Keytruda Qlex (FDA-approved September 19, 2025), expanded Keytruda into earlier-stage cancers, and bought late-stage or commercial assets: Verona Pharma for about $10 billion (completed October 2025, adding COPD drug Ohtuvayre), Cidara Therapeutics for about $9.2 billion (completed January 202…
Competitive advantage
Merck's insurmountable competitive moat is built upon Keytruda's extraordinary clinical efficacy across dozens of tumor types, its entrenched standard-of-care position in first-line non-small cell lung cancer, and Gardasil's global dominance in preventative oncology.
Questions about Eli Lilly vs Merck
Which company has higher revenue — Eli Lilly and Company or Merck & Co., Inc.?
Eli Lilly and Company had $65.2B (FY2025), while Merck & Co., Inc. had $65.0B (FY2025). By latest annual revenue, Eli Lilly and Company is the larger business, with Merck & Co., Inc. showing a smaller revenue base.
What is the market cap of Eli Lilly and Company vs Merck & Co., Inc.?
Eli Lilly and Company's market capitalisation stands at $1.06T, while Merck & Co., Inc.'s is $368.3B. Eli Lilly and Company carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Merck & Co., Inc..
How does revenue per employee compare for Eli Lilly and Company and Merck & Co., Inc.?
Eli Lilly and Company has $1.30M / employee in revenue per employee, while Merck & Co., Inc. has $867k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.
How do Eli Lilly and Company and Merck & Co., Inc. make money?
Eli Lilly and Company and Merck & Co., Inc. generate revenue in fundamentally different ways. Eli Lilly and Company: Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience. Merck & Co., Inc.: Merck & Co., Inc. (known as MSD outside the United States and Canada) is an innovation-led global biopharmaceutical company that discovers, develops, and delivers prescription medicines, vaccines, biologic therapies, and animal health products.
Which company is valued higher relative to revenue — Eli Lilly and Company or Merck & Co., Inc.?
On a price-to-sales (P/S) basis, Eli Lilly and Company trades at 16.3x P/S and Merck & Co., Inc. at 5.7x P/S. Eli Lilly and Company commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Merck & Co., Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Eli Lilly and Company bigger than Merck & Co., Inc.?
By last reported revenue, Eli Lilly and Company ($65.2B (FY2025)) is the larger company compared to Merck & Co., Inc. ($65.0B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Eli Lilly vs Merck overview